EUROLIDE 4MG INJECTION 4 ML

EUROLIDE 4MG/4 ML works by suppressing the production of certain hormones, thereby reducing symptoms associated with conditions like prostate cancer, endometriosis, and uterine fibroids.

EUROLIDE 4MG/4 ML is a GnRH agonist that acts on the pituitary gland, leading to the suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release. By desensitizing the GnRH receptors, EUROLIDE 4MG/4 ML inhibits the production of sex hormones, such as <TESTOSTERONE> in males and estrogen in females. In prostate cancer, it causes a decrease in <TESTOSTERONE> levels, which helps to slow the growth and spread of cancer cells. In conditions like endometriosis, EUROLIDE 4MG/4 ML reduces estrogen levels, resulting in the suppression of the endometrial tissue's growth and relieving associated symptoms. For uterine fibroids, EUROLIDE 4MG/4 ML creates a state of medical menopause, reducing estrogen levels and shrinking the fibroids. In cases of precocious puberty, it temporarily halts the early onset of puberty by inhibiting the release of LH and FSH. The precise dosage and duration of treatment vary depending on the specific condition being treated.